White paper

Decision Science Asset Diversification Versus Concentration

The pharmaceutical industry continues to undergo tremendous changes. The questions for executives are how do these changes affect the direction of investments in new decision scien ...

White paper

Achieving Sales Operations Excellence With Intelligent Roster Management

Effective roster management has long been an overlooked topic in Pharma commercial operations. At any point in time, it is critical for the Sales Operations business processes to h ...

White paper

The Reasons for and Solutions to Chronic Drug Shortages in the United States

This white paper will briefly address the questions and present the key reasons for and solutions to the existence of chronic drug shortages in the US. It will also discuss the rol ...

White paper

Pricing and Market Effects of Biosimilar Entry in the US

This white paper will provide insights into key questions as they pertain to the entry of biosimilars in the US market, pricing and market effects and the future of biosimilars in ...

White paper

The Importance of Governance in Your Incentive Compensation Program

In this white paper, we address the importance of IC Governance, its team make up, roles and responsibilities. We also go into the details of governing best practices towards plan ...

White paper

Designing Incentive Compensation Plans for Specialty Products

The focus of this white paper is to highlight key challenges in designing IC plans for promoting specialty drugs by a pharmaceutical sales force and recommended best practices when ...

Article

Sales Analytics and Big Data Developments Needed Now to Address Sales Force Issues

The biopharmaceutical industry is undergoing significant changes. Most importantly, there is a shift toward greater company R&D focus on and launching of specialty medicines. W ...

Industry Survey

State Of Commercial Excellence 2017 – Part 1

Axtria recently launched a Commercial Excellence Survey to better understand the readiness of commercial organizations when facing these changing market realities. The survey inclu ...

White paper

Is it Time to Adjust the Pharma PDE Sales Force Optimization Model?

The question this white paper addresses is straightforward – Is it time to adjust the long-standing pharma PDE (primary detail equivalent) sales force optimization model? The PDE ...

White paper

Global Pharma Pricing and Market Effects of President Trump’s Proposed Policies

President Trump campaigned to use the buying power of the federal government to directly negotiate downward the prices of drugs used by Medicare patients. The question this white p ...

Blog

Implications From HEOR And RWE Models For Biopharmaceutical Commercial Analytics

The following blog is an expanded summary of proposed research accepted for delivery at the upcoming 22nd ISPOR Annual International Meeting, Research Poster Presentations – ...

Whitepaper

Make US Pharma Great Again!? – Part 2

Recent quotes from pharma CEOs about the effects of President Trump’s potential policy actions clearly point to added elements of risk and uncertainty for the industry.This comes ...

White paper

Decision Science Asset Diversification Versus Concentration

The pharmaceutical industry continues to undergo tremendous changes. The questions for executives are how do these changes affect the direction of investments in new decision scien ...

White paper

Achieving Sales Operations Excellence With Intelligent Roster Management

Effective roster management has long been an overlooked topic in Pharma commercial operations. At any point in time, it is critical for the Sales Operations business processes to h ...

White paper

The Reasons for and Solutions to Chronic Drug Shortages in the United States

This white paper will briefly address the questions and present the key reasons for and solutions to the existence of chronic drug shortages in the US. It will also discuss the rol ...

White paper

Pricing and Market Effects of Biosimilar Entry in the US

This white paper will provide insights into key questions as they pertain to the entry of biosimilars in the US market, pricing and market effects and the future of biosimilars in ...

White paper

The Importance of Governance in Your Incentive Compensation Program

In this white paper, we address the importance of IC Governance, its team make up, roles and responsibilities. We also go into the details of governing best practices towards plan ...

White paper

Designing Incentive Compensation Plans for Specialty Products

The focus of this white paper is to highlight key challenges in designing IC plans for promoting specialty drugs by a pharmaceutical sales force and recommended best practices when ...

Article

Sales Analytics and Big Data Developments Needed Now to Address Sales Force Issues

The biopharmaceutical industry is undergoing significant changes. Most importantly, there is a shift toward greater company R&D focus on and launching of specialty medicines. W ...

Industry Survey

State Of Commercial Excellence 2017 – Part 1

Axtria recently launched a Commercial Excellence Survey to better understand the readiness of commercial organizations when facing these changing market realities. The survey inclu ...

White paper

Is it Time to Adjust the Pharma PDE Sales Force Optimization Model?

The question this white paper addresses is straightforward – Is it time to adjust the long-standing pharma PDE (primary detail equivalent) sales force optimization model? The PDE ...

White paper

Global Pharma Pricing and Market Effects of President Trump’s Proposed Policies

President Trump campaigned to use the buying power of the federal government to directly negotiate downward the prices of drugs used by Medicare patients. The question this white p ...

Blog

Implications From HEOR And RWE Models For Biopharmaceutical Commercial Analytics

The following blog is an expanded summary of proposed research accepted for delivery at the upcoming 22nd ISPOR Annual International Meeting, Research Poster Presentations – ...

Whitepaper

Make US Pharma Great Again!? – Part 2

Recent quotes from pharma CEOs about the effects of President Trump’s potential policy actions clearly point to added elements of risk and uncertainty for the industry.This comes ...

White paper

Decision Science Asset Diversification Versus Concentration

The pharmaceutical industry continues to undergo tremendous changes. The questions for executives are how do these changes affect the direction of investments in new decision scien ...

White paper

Achieving Sales Operations Excellence With Intelligent Roster Management

Effective roster management has long been an overlooked topic in Pharma commercial operations. At any point in time, it is critical for the Sales Operations business processes to h ...

White paper

The Reasons for and Solutions to Chronic Drug Shortages in the United States

This white paper will briefly address the questions and present the key reasons for and solutions to the existence of chronic drug shortages in the US. It will also discuss the rol ...

White paper

Pricing and Market Effects of Biosimilar Entry in the US

This white paper will provide insights into key questions as they pertain to the entry of biosimilars in the US market, pricing and market effects and the future of biosimilars in ...

White paper

The Importance of Governance in Your Incentive Compensation Program

In this white paper, we address the importance of IC Governance, its team make up, roles and responsibilities. We also go into the details of governing best practices towards plan ...

White paper

Designing Incentive Compensation Plans for Specialty Products

The focus of this white paper is to highlight key challenges in designing IC plans for promoting specialty drugs by a pharmaceutical sales force and recommended best practices when ...

Article

Sales Analytics and Big Data Developments Needed Now to Address Sales Force Issues

The biopharmaceutical industry is undergoing significant changes. Most importantly, there is a shift toward greater company R&D focus on and launching of specialty medicines. W ...

Industry Survey

State Of Commercial Excellence 2017 – Part 1

Axtria recently launched a Commercial Excellence Survey to better understand the readiness of commercial organizations when facing these changing market realities. The survey inclu ...

White paper

Is it Time to Adjust the Pharma PDE Sales Force Optimization Model?

The question this white paper addresses is straightforward – Is it time to adjust the long-standing pharma PDE (primary detail equivalent) sales force optimization model? The PDE ...

White paper

Global Pharma Pricing and Market Effects of President Trump’s Proposed Policies

President Trump campaigned to use the buying power of the federal government to directly negotiate downward the prices of drugs used by Medicare patients. The question this white p ...

Blog

Implications From HEOR And RWE Models For Biopharmaceutical Commercial Analytics

The following blog is an expanded summary of proposed research accepted for delivery at the upcoming 22nd ISPOR Annual International Meeting, Research Poster Presentations – ...

Whitepaper

Make US Pharma Great Again!? – Part 2

Recent quotes from pharma CEOs about the effects of President Trump’s potential policy actions clearly point to added elements of risk and uncertainty for the industry.This comes ...

White paper

Decision Science Asset Diversification Versus Concentration

The pharmaceutical industry continues to undergo tremendous changes. The questions for executives are how do these changes affect the direction of investments in new decision scien ...

White paper

Achieving Sales Operations Excellence With Intelligent Roster Management

Effective roster management has long been an overlooked topic in Pharma commercial operations. At any point in time, it is critical for the Sales Operations business processes to h ...

White paper

The Reasons for and Solutions to Chronic Drug Shortages in the United States

This white paper will briefly address the questions and present the key reasons for and solutions to the existence of chronic drug shortages in the US. It will also discuss the rol ...

White paper

Pricing and Market Effects of Biosimilar Entry in the US

This white paper will provide insights into key questions as they pertain to the entry of biosimilars in the US market, pricing and market effects and the future of biosimilars in ...

White paper

The Importance of Governance in Your Incentive Compensation Program

In this white paper, we address the importance of IC Governance, its team make up, roles and responsibilities. We also go into the details of governing best practices towards plan ...

White paper

Designing Incentive Compensation Plans for Specialty Products

The focus of this white paper is to highlight key challenges in designing IC plans for promoting specialty drugs by a pharmaceutical sales force and recommended best practices when ...

Article

Sales Analytics and Big Data Developments Needed Now to Address Sales Force Issues

The biopharmaceutical industry is undergoing significant changes. Most importantly, there is a shift toward greater company R&D focus on and launching of specialty medicines. W ...

Industry Survey

State Of Commercial Excellence 2017 – Part 1

Axtria recently launched a Commercial Excellence Survey to better understand the readiness of commercial organizations when facing these changing market realities. The survey inclu ...

White paper

Is it Time to Adjust the Pharma PDE Sales Force Optimization Model?

The question this white paper addresses is straightforward – Is it time to adjust the long-standing pharma PDE (primary detail equivalent) sales force optimization model? The PDE ...

White paper

Global Pharma Pricing and Market Effects of President Trump’s Proposed Policies

President Trump campaigned to use the buying power of the federal government to directly negotiate downward the prices of drugs used by Medicare patients. The question this white p ...

Blog

Implications From HEOR And RWE Models For Biopharmaceutical Commercial Analytics

The following blog is an expanded summary of proposed research accepted for delivery at the upcoming 22nd ISPOR Annual International Meeting, Research Poster Presentations – ...

Whitepaper

Make US Pharma Great Again!? – Part 2

Recent quotes from pharma CEOs about the effects of President Trump’s potential policy actions clearly point to added elements of risk and uncertainty for the industry.This comes ...

Let us help your business today.
Contact us now to start your journey.